MXPA05010712A - Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. - Google Patents

Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.

Info

Publication number
MXPA05010712A
MXPA05010712A MXPA05010712A MXPA05010712A MXPA05010712A MX PA05010712 A MXPA05010712 A MX PA05010712A MX PA05010712 A MXPA05010712 A MX PA05010712A MX PA05010712 A MXPA05010712 A MX PA05010712A MX PA05010712 A MXPA05010712 A MX PA05010712A
Authority
MX
Mexico
Prior art keywords
quinoline
derivatives
treatment
airways diseases
compounds
Prior art date
Application number
MXPA05010712A
Other languages
English (en)
Inventor
Simon James Watson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0307856A external-priority patent/GB0307856D0/en
Priority claimed from GB0311462A external-priority patent/GB0311462D0/en
Priority claimed from GB0313489A external-priority patent/GB0313489D0/en
Priority claimed from GB0316657A external-priority patent/GB0316657D0/en
Priority claimed from GB0316656A external-priority patent/GB0316656D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05010712A publication Critical patent/MXPA05010712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la formula (I), en la forma libre o en forma de su sal, enla que -C-Y-, R1 y R2 son G, tienen los significados que estan indicados en la memoria descriptiva, son utiles para tratar condiciones que se previenen o alivian mediante la activacion del (beta2-adrenorreceptor. Tambien se describen composiciones farmaceuticas que contienen los compuestos y un proceso para preparar los compuestos.
MXPA05010712A 2003-04-04 2004-04-02 Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. MXPA05010712A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0307856A GB0307856D0 (en) 2003-04-04 2003-04-04 Organic compounds
GB0311462A GB0311462D0 (en) 2003-05-19 2003-05-19 Organic compounds
GB0313489A GB0313489D0 (en) 2003-06-11 2003-06-11 Organic compounds
GB0316657A GB0316657D0 (en) 2003-07-16 2003-07-16 Organic compounds
GB0316656A GB0316656D0 (en) 2003-07-16 2003-07-16 Organic compounds
PCT/EP2004/003516 WO2004087142A1 (en) 2003-04-04 2004-04-02 Quinoline-2-one-derivatives for the treatment of airways diseases

Publications (1)

Publication Number Publication Date
MXPA05010712A true MXPA05010712A (es) 2005-12-15

Family

ID=33136224

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010712A MXPA05010712A (es) 2003-04-04 2004-04-02 Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.

Country Status (13)

Country Link
US (1) US7745462B2 (es)
EP (1) EP1613315B1 (es)
JP (1) JP4516064B2 (es)
AT (1) ATE421322T1 (es)
AU (1) AU2004226824B2 (es)
BR (1) BRPI0409198A (es)
CA (1) CA2521271C (es)
DE (1) DE602004019198D1 (es)
ES (1) ES2320994T3 (es)
MX (1) MXPA05010712A (es)
PL (1) PL1613315T3 (es)
PT (1) PT1613315E (es)
WO (1) WO2004087142A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
ES2530991T3 (es) * 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
KR101402398B1 (ko) * 2006-06-30 2014-06-03 노파르티스 아게 퀴놀리논 유도체 및 이의 제약 조성물
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
PE20080610A1 (es) 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101230058A (zh) * 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
JP5438028B2 (ja) * 2008-01-23 2014-03-12 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2011349551A1 (en) * 2010-12-22 2013-06-27 Onyx Pharmaceuticals, Inc. Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (g) quinazoline trisodium salt
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
WO2014194741A1 (zh) * 2013-06-07 2014-12-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
CN103408465B (zh) * 2013-07-29 2015-08-26 南开大学 一种n-二取代苯基甲基缬氨酰胺氨基甲酸酯衍生物及应用
WO2016038628A2 (en) * 2014-09-09 2016-03-17 Reddy G Pratap A process for preparing olodaterol and intermediates thereof
PT3216790T (pt) * 2014-11-05 2019-11-19 Jiangsu Hengrui Medicine Co Forma cristalina de bissulfato inibidor de jak cinase e um seu método de preparação
IL264446B1 (en) 2016-07-29 2024-05-01 Pgi Drug Discovery Llc Compounds and compositions and their use
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6026784B2 (ja) * 1975-04-29 1985-06-25 樋口 佳成 新規カルボスチリル誘導体
JPS597706B2 (ja) 1975-06-13 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS597707B2 (ja) * 1975-06-23 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノ セイゾウホウ
JPS57154129A (en) * 1981-03-16 1982-09-22 Otsuka Pharmaceut Co Ltd Cardiotonic drug
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPS6010033B2 (ja) * 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体の製造法
JPS6010032B2 (ja) * 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体
WO1993018007A1 (en) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
PT1613315E (pt) 2009-04-22
EP1613315A1 (en) 2006-01-11
JP2006523190A (ja) 2006-10-12
CA2521271C (en) 2011-01-04
DE602004019198D1 (de) 2009-03-12
PL1613315T3 (pl) 2009-07-31
EP1613315B1 (en) 2009-01-21
AU2004226824A1 (en) 2004-10-14
WO2004087142A1 (en) 2004-10-14
US20070066607A1 (en) 2007-03-22
US7745462B2 (en) 2010-06-29
ATE421322T1 (de) 2009-02-15
AU2004226824B2 (en) 2008-05-01
ES2320994T3 (es) 2009-06-01
JP4516064B2 (ja) 2010-08-04
CA2521271A1 (en) 2004-10-14
BRPI0409198A (pt) 2006-05-02

Similar Documents

Publication Publication Date Title
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
GB0305152D0 (en) Organic compounds
TW200519106A (en) Organic compounds
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
TW200517386A (en) Organic compounds
TW200630374A (en) Thiazolyldihydroindazoles
MY156407A (en) 5-phenylthiazole derivatives and use as p13 kinase inhibitors
SE0200920D0 (sv) Novel compounds
TW200616995A (en) Novel compounds
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
DE602004021472D1 (en) Pyrimiidinverbindungen
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
TW200738659A (en) Novel compounds
TW200505920A (en) Organic compounds
SI1751093T1 (sl) Substituirani derivati cikloheksilocetne kisline
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
MY146802A (en) Novel drugs for treating respiratory diseases
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
SI1606288T1 (sl) Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine
WO2007068473A3 (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration